Page 6 - Michael Benkowitz News Today : Breaking News, Live Updates & Top Stories | Vimarsana

MedCity News United Therapeutics notches another FDA approval for lung drug The FDA decision for Tyvaso as a treatment for pulmonary arterial hypertension in patients who have interstitial lung disease is the second approval for the United Therapeutics drug. The additional indication gives the company another way to grow revenue for the drug, which faces generic competition. Shares0   United Therapeutics has received FDA approval for its drug, treprostinil, as a treatment for high blood pressure affecting the lungs in patients who have a group of rare respiratory disorders called interstit...

Operator Good morning, and welcome to the United Therapeutics Corporation Fourth Quarter 2020 Earnings Call. My name is Kenzie, and I will be your conference operator today. [Operator Instructions] I will now turn the conference call over to Mr. Dewey Steadman, Head of Investor Relations at United Therapeutics. Dewey Steadman -- Head of Investor Relations Good morning. It's my pleasure to welcome you to the United Therapeutics Corporation Fourth Quarter 2020 Earnings Call. Accompanying me on today's call are Dr. Martine Rothblatt, our Chairman and Chief Executive Officer; Mr. Michael Benkowi...

United Therapeutics Corporation To Present At The 41st Annual Cowen Health Care Conference News provided by Share this article Share this article SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 24, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Mr. Michael Benkowitz, President and Chief Operating Officer of United Therapeutics, will provide an overview and update on the company's business during a fireside chat session at the 41st annual Cowen Health Care Conference. The session will take place virtually on Wednesday March 3, 2021, from 10...

United Therapeutics Announces New England Journal of Medicine Publication of the INCREASE Study Evaluating Tyvaso® in Pulmonary Hypertension Associated with Interstitial Lung Disease INCREASE Study is First to Demonstrate a Clear Benefit in Patients with PH-ILD, a Life-threatening Disease with No Currently FDA-Approved Treatments Company to host a webcast detailing the INCREASE study results on Tuesday, January 19, 2021 at 4:30 p.m. E.T. News provided by Share this article Share this article SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Jan. 13, 2021 /PRNewswire/ -- United Therapeuti...

United Therapeutics Announces Agreement To Acquire Priority Review Voucher Voucher expected to be applied to the forthcoming NDA for Tyvaso DPI™ News provided by Share this article Share this article SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Dec. 28, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today an agreement to acquire a Rare Pediatric Disease Priority Review Voucher (PRV), which it plans to use with a forthcoming New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA). The PRV entitles the holder to designate an NDA for ...